Log in

NASDAQ:DVAX - Dynavax Technologies Stock Price, Forecast & News

$5.70
+0.01 (+0.18 %)
(As of 12/8/2019 09:17 AM ET)
Today's Range
$5.64
Now: $5.70
$5.85
50-Day Range
$4.08
MA: $5.32
$6.00
52-Week Range
$2.60
Now: $5.70
$12.42
Volume848,149 shs
Average Volume994,313 shs
Market Capitalization$478.00 million
P/E RatioN/A
Dividend YieldN/A
Beta0.56
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:DVAX
CUSIP26815810
Phone510-848-5100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.20 million
Book Value$1.01 per share

Profitability

Net Income$-158,900,000.00
Net Margins-519.95%

Miscellaneous

Employees249
Market Cap$478.00 million
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive DVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter.


Dynavax Technologies (NASDAQ:DVAX) Frequently Asked Questions

What is Dynavax Technologies' stock symbol?

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies Co. (NASDAQ:DVAX) issued its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing the Zacks' consensus estimate of ($0.40) by $0.10. The biopharmaceutical company had revenue of $10.58 million for the quarter, compared to analyst estimates of $10.31 million. Dynavax Technologies had a negative return on equity of 399.60% and a negative net margin of 519.95%. The company's revenue for the quarter was up 624.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.65) EPS. View Dynavax Technologies' Earnings History.

When is Dynavax Technologies' next earnings date?

Dynavax Technologies is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Dynavax Technologies.

What price target have analysts set for DVAX?

5 analysts have issued twelve-month price objectives for Dynavax Technologies' shares. Their forecasts range from $13.00 to $20.00. On average, they expect Dynavax Technologies' stock price to reach $15.33 in the next year. This suggests a possible upside of 169.0% from the stock's current price. View Analyst Price Targets for Dynavax Technologies.

What is the consensus analysts' recommendation for Dynavax Technologies?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dynavax Technologies.

Has Dynavax Technologies been receiving favorable news coverage?

News articles about DVAX stock have been trending somewhat positive recently, according to InfoTrie. The research group rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Dynavax Technologies earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Dynavax Technologies.

Who are some of Dynavax Technologies' key competitors?

What other stocks do shareholders of Dynavax Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Array Biopharma (ARRY), United Continental (UAL), Kite Pharma (KITE), Cara Therapeutics (CARA) and Micron Technology (MU).

Who are Dynavax Technologies' key executives?

Dynavax Technologies' management team includes the folowing people:
  • Mr. Eddie Gray, CEO & Director (Age 60)
  • Dr. Dennis A. Carson Ph.D., M.D., Co-Founder, Director & Member of Scientific Advisory Board (Age 72)
  • Mr. Michael S. Ostrach, CFO, Chief Bus. Officer & Sr. VP (Age 67)
  • Mr. David F. Novack, Sr. VP of Operations & Quality (Age 57)
  • Dr. Robert L. Coffman, Chief Scientific Officer & Sr. VP (Age 72)

Who are Dynavax Technologies' major shareholders?

Dynavax Technologies' stock is owned by a number of of retail and institutional investors. Top institutional investors include Chicago Capital LLC (6.72%), State Street Corp (1.76%), Point72 Asset Management L.P. (1.18%), Millennium Management LLC (0.99%), California State Teachers Retirement System (0.15%) and Rhumbline Advisers (0.15%). Company insiders that own Dynavax Technologies stock include David F Novack, David Louis Johnson, Francis Cano, Michael S Ostrach and Robert Coffman. View Institutional Ownership Trends for Dynavax Technologies.

Which institutional investors are selling Dynavax Technologies stock?

DVAX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. Company insiders that have sold Dynavax Technologies company stock in the last year include David Louis Johnson, Michael S Ostrach and Robert Coffman. View Insider Buying and Selling for Dynavax Technologies.

Which institutional investors are buying Dynavax Technologies stock?

DVAX stock was purchased by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Point72 Asset Management L.P., State Street Corp, Virtu Financial LLC, California State Teachers Retirement System, Barclays PLC, Ingalls & Snyder LLC and California Public Employees Retirement System. View Insider Buying and Selling for Dynavax Technologies.

How do I buy shares of Dynavax Technologies?

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Dynavax Technologies' stock price today?

One share of DVAX stock can currently be purchased for approximately $5.70.

How big of a company is Dynavax Technologies?

Dynavax Technologies has a market capitalization of $478.00 million and generates $8.20 million in revenue each year. The biopharmaceutical company earns $-158,900,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Dynavax Technologies employs 249 workers across the globe.View Additional Information About Dynavax Technologies.

What is Dynavax Technologies' official website?

The official website for Dynavax Technologies is http://www.dynavax.com/.

How can I contact Dynavax Technologies?

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]


MarketBeat Community Rating for Dynavax Technologies (NASDAQ DVAX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  384 (Vote Outperform)
Underperform Votes:  385 (Vote Underperform)
Total Votes:  769
MarketBeat's community ratings are surveys of what our community members think about Dynavax Technologies and other stocks. Vote "Outperform" if you believe DVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Featured Article: 52-Week High/Low

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel